Press Releases April 8, 2026 08:00 PM

Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th

Indivior to announce Q1 2026 financial results and host leadership webcast on April 30th.

By Maya Rios INDV
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
INDV

Indivior Pharmaceuticals will release its first quarter 2026 financial results on April 30, 2026, followed by a live webcast presentation by CEO Joe Ciaffoni and other executives. The company is a leader in long-acting injectable treatments for opioid use disorder and emphasizes its commitment to advancing treatments and understanding of OUD.

Key Points

  • Indivior focuses on evidence-based treatments for opioid use disorder, positioning it as a key player in the addiction medicine sector.
  • The upcoming financial results and webcast provide transparency and direct communication with investors.
  • The company highlights its renewed commitment to individuals living with OUD and ongoing scientific advancement, impacting healthcare and pharmaceutical sectors.

RICHMOND, Va., April 09, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, at 7:00 a.m. U.S. EDT. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior’s leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EDT.

Access to the Live Webcast Presentation:

The webcast event and materials can be accessed on the “Investors” section of the company’s website at www.indivior.com before the event begins.

Live webcast link: https://edge.media-server.com/mmc/p/3k7nbxjp

Participants may access the presentation telephonically by registering with the following link:

https://register-conf.media-server.com/register/BIea9b995134de41e68f49a057c2a6cb66

(Registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration)

A replay of the presentation will be available at www.indivior.com.

About Indivior
As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine, developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities – we are powering recovery and renewing hope. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/Indivior. 

For Further Information

Investors:
Jason Thompson
Indivior Pharmaceuticals
Tel: 804-402-7123
E-mail: [email protected]

Media:
Cassie France-Kelly
Indivior Pharmaceuticals
Tel: 804-594-0836
E-Mail: [email protected]


Risks

  • Financial results could fall short of market expectations, affecting stock performance and investor confidence.
  • Regulatory changes in healthcare or drug approval processes could impact Indivior's operations and market access.
  • Market competition in addiction treatment pharmaceuticals may increase, putting pressure on sales and growth prospects.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026